Physicians' attitudes toward anticoagulant therapy in patients with chronic atrial fibrillation

Internal Medicine

Volumn 43, Issue 7, 2004, Pages 553-560

  Maeda, Kenji ^f   Sakai, Tatsuya ^f   Hira, Kenji ^f   Sato, T Shun ^a   Bito, Seiji ^b   Asai, Atsushi ^a   Hayano, Keiko ^c   Matsumura, Shinji ^d   Yamashiro, Seiji ^e   Fukui, Tsuguya ^f  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e SAGA UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Japan; Physician practice patterns; Questionnaires; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; EXPERIENCE; FEMALE; GENERAL PRACTICE; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; JAPAN; MALE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SOCIETY; PHYSICIAN ATTITUDE; QUESTIONNAIRE; RESPONSIBILITY; RISK ASSESSMENT; TEACHING HOSPITAL; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; ATTITUDE OF HEALTH PERSONNEL; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; DRUG UTILIZATION; ELECTROCARDIOGRAPHY; FEMALE; HEALTH CARE SURVEYS; HUMANS; JAPAN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROBABILITY; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; WARFARIN;

EID: 4444262323     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.553     Document Type: Article

References (35)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983-988, 1991.
2. Tanaka H, Hayashi M, Date C, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction. Stroke 16: 773-780, 1985.
3. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1: 175-179, 1989.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323: 1505-1511, 1990.
5. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18: 349-355, 1991.
6. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84: 527-539, 1991.
7. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327: 1406-1412, 1992 (Erratum in: N Engl J Med 328: 148, 1993).
8. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342: 1255-1262, 1993.
9. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 51: 674-681, 1998.
10. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 119 (1 Suppl): 194S-206S, 2001.
11. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38: 1231-1266, 2001.
12. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 160: 41-46, 2000.
13. Tomita F, Kohya T, Sakurai M, Kitabatake A. Prevalence and clincial characteristics of patients with atrial fibrillation - Analysis of 19,000 cases in Hokkaido -. Recent advances in clinical pharmacology 19: 167-172, 1998.
14. Research Group for Antiarrhythmic Drug Therapy. Survey of atrial fibrillation and thromboembolism in the elderly: a multicenter cooperative study. J Cardiol 33: 27-35, 1999.
15. Hirano T, Oita J, Yamaguchi T. Classification of ischemic stroke and frequency distribution. Nippon Rinsho 51 (Suppl): 337-342, 1993.
16. Fujishima M. Cerebrovascular disorders among Japanese. Nippon Naika Gakkai Zasshi 85: 1407-1418, 1996.
17. Kita Y, Okayama A, Ueshima H, et al. Stroke incidence and case fatality in Shiga, Japan 1989-1993. Int J Epidemiol 28: 1059-1065, 1999.
18. Kumasaka N, Sakuma M, Shirato K. Incidence of pulmonary thromboembolism in Japan. Jpn Circ J 63: 439-441, 1999.
19. Diggle PJ, Heagerty PJ, Liang KY, Zeger SL. Analysis of longitudinal data. 2nd. ed. Oxford University Press, New York, 2002.
20. SAS. SAS/STAT: User's Guide, Version8. SAS Institute, Cary, NC, 2000.
21. Hart RG, Halperin JL, Pearce LA, Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 138: 831-839, 2003.
22. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 11: 721-728, 1996.
23. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 157: 1237-1240, 1997.
24. Laupacis A, Sullivan K. Canadian atrial fibrillation anticoagulation study: were the patients subsequently treated with warfarin? Canadian Atrial Fibrillation Anticoagulation Study Group. CMAJ 154: 1669-1674, 1996.
25. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 11: 713-720, 1996.
26. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 28: 2382-2389, 1997.
27. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 157: 978-984, 1997.
28. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 28: 72-76, 1997.
29. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 157: 441-445, 1997.
30. Brass LM, Krumholz HM, Scinto JD, Mathur D, Radford M. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 158: 2093-2100, 1998.
31. The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 14: 695-702, 1998.
32. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131: 927-934, 1999.
33. Wetle T. Age as a risk factor for inadequate treatment. JAMA 258: 516, 1987.
34. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87: 144-152, 1989.
35. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120: 897-902, 1994.